The idea is to head off serious gathering threats without getting thrown off the scent by strains unlikely to proliferate.
AI melanoma detectors that equaled or bettered dermatologists in clinical trials have stumbled on the way to the real world of patient care.
The NIH, FDA and Bill and Melinda Gates Foundation are working with a San Francisco startup whose calling card is an AI-enabled engine that renders patient data unidentifiable by reproducing it in synthetic versions.
